Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. An increasing number of epilepsy cases is expected to drive growth of the global epileptic seizures treatment market. For instance, according to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally had epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China.
Moreover, increasing launches of drugs for treatment of epilepsy is expected to create conducive environment for the market growth. For instance, in 2016, UCB Pharma Limited received the U.S. FDA approval for Briviact, for the treatment of patients with partial onset of seizures. Moreover, Mylan launched generic, Felbatol tablets for the treatment of epileptic seizures, in the U.S. after receiving approval from the U.S. Food & Drug Administration in 2016. These factors are expected to boost the market growth over the forecast period.
Market Dynamics
The increasing prevalence of epilepsy in adults and children, across the globe is expected to drive growth of the epileptic seizures treatment market during the forecast period. According to the WHO, around one-third of children with epilepsy can be assigned to a specific epilepsy syndrome, as defined by the most recently proposed system for organization of epilepsy syndrome. According to the Society of Neuroscience, in 2015, epilepsy affected around 10.5 million children worldwide, and the types and severity of the disorder varied significantly. Moreover, according to the American Academy of Pediatrics data published in April 2017, epilepsy affects 0.5% to 1% of children globally, and is the most frequently occurring chronic neurologic condition in childhood.
However, non‐conventional anti-epileptic treatments and non‐pharmacological approaches can potentially help in reduction of seizures or anti-epileptic drug toxicity. For instance, there has been increasing preference for alternative therapy for epilepsy such as corticosteroids, immunoglobulins, melatonin, and vitamins for treating children. Other than supplemental therapy, there are certain techniques that can help reduce epileptic seizures such as avoidance technique, which involves avoiding activities that can induce a seizure such as flickering lights, listening to specific type or piece of music, eating, reading, and immersion in hot water, chess playing, or brushing hair. Thus, these factors are expected to restrain the epileptic seizures treatment market growth. Other non‐pharmacological treatments for epilepsy in children include herbal medicine, homeopathy, yoga, aromatherapy, and coping strategies.
Key features of the study:
- This report provides in-depth analysis of the global epileptic seizures treatment market, market size (US$ Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global epileptic seizures treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global epileptic seizures treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for epileptic seizures treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- Global Epileptic Seizures Treatment Market, By Drug Type:
- First Generation
- Second Generation
- Third Generation
- Global Epileptic Seizures Treatment Market, By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- Global Epileptic Seizures Treatment Market, By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- Global Epileptic Seizures Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Epileptic Seizures Treatment Market, By Region:
- North America
- By Country:
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Type:
- First Generation
- Second Generation
- Third Generation
- By Seizure Type:
- Partial Seizures
- Generalized Seizures
- Unclassified Seizures
- By Route of Administration:
- Oral/Buccal
- Nasal
- Rectal
- Parenteral
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Novartis AG *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Sanofi S.A.
- Mylan N.V.
- Bausch Health Companies Inc.
- UCB S.A
- Eisai Co. Ltd.
- Abbott Laboratories
- Sumitomo Dainippon Pharma Co., Ltd.
- GW Pharmaceuticals Plc
- Marinus Pharmaceuticals, Inc.
- Lundbeck A/S
- Takeda Pharmaceutical Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
